Pfizer, BioNTech's Covid-19 vaccines get US FDA's 'fast track' status


Two experimental coronavirus vaccines jointly developed by German biotech firm BioNTech and US pharmaceutical giant Pfizer have received 'fast track' designation from the US drug regulator, the companies said on Monday. The candidates, BNT162b1 and BNT162b2, are the most advanced of the at least four vaccines being assessed by the companies in ongoing trials in the United States and Germany.

Pfizer's shares were up about 2 per cent and US-listed shares of BioNTech were up about 6 per cent before the bell. Earlier.

This article is no longer available in our repository.

There could be multiple reasons for this.